Loading…
Deluxe IV Aesthetics was cited for misbranding compounded semaglutide and tirzepatide products by falsely representing itself as the manufacturer on product labels and advertising when it was not the actual compounder, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's website made comparative claims equating its compounded drugs to FDA-approved branded products (Ozempic®, Mounjaro®, Wegovy®, and Zepbound®) without appropriate qualifications, further constituting false or misleading promotion. These violations resulted in the products being unlawfully introduced into interstate commerce.